Research
Hormonal
The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.
Practitioners should be aware of the limitations of current oral obesity treatments.
StrongSupportsmedium confidence
The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.
Why this rating
The claim is based on a comprehensive review of existing literature.
Source
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil et al. · Biomedicine & Pharmacotherapy · 2024
DOI 10.1016/j.biopha.2024.116245
reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →